Literature DB >> 25617815

Twenty-year brain magnetic resonance imaging follow-up study in Systemic Lupus Erythematosus: Factors associated with accrual of damage and central nervous system involvement.

Matteo Piga1, Maria Teresa Peltz2, Carlo Montaldo3, Daniela Perra4, Giovanni Sanna5, Alberto Cauli6, Alessandro Mathieu7.   

Abstract

To evaluate the long-term progression of cerebral MRI abnormalities in patients with longstanding SLE, 30 patients (age 53.5 ± 11.3) underwent brain MRI at baseline (b-MRI) and after 19.4 ± 3.7 years of follow-up (fu-MRI). Two neuroradiologists visually analyzed the MRIs comparing: 1) white matter hyperintensities (WMHIs), 2) cerebral volume, and 3) parenchymal defects; these outcomes were also built in a modified MRI scoring system (mMSS) to estimate the cumulative parenchymal damage. The independent risk factors for accrual of MRI brain damage, as well as the association between MRI abnormalities and the development of new neuropsychiatric (NP) manifestations classified according to the 1999 ACR case definition were also analyzed. Twenty-three patients (76.7%) showed worsening of mMSS; 19 (63.3%) had increased number and volume of WMHIs, 8 (26.7%) had significant cerebral volume loss, and 6 (20%) showed new ischemic parenchymal lesions. Only 6 patients had normal MRI. Antimalarial agents (p=0.006; OR 0.08) were protective against worsening of WMHIs. High cumulative dose of corticosteroids (p=0.026; OR 8.8) and dyslipidemia (p=0.044; OR 10.1) were associated with increased mMSS and cerebral volume loss, respectively. Higher mMSS score at baseline was independently associated with worsening of WMHIs (p=0.001; OR 5.7) and development of new NP events (p=0.019; OR 2.0); higher load of deep WMHIs at b-MRI (p=0.018; OR 2.0) was independently associated with stroke risk. This study shows that MRI brain damage in SLE patients progresses independently from NP involvement as effect of potentially modifiable risk factors and it is associated with increased risk of new NP events.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brain; MRI; Neuropsychiatric SLE; SLE; Stroke

Mesh:

Year:  2015        PMID: 25617815     DOI: 10.1016/j.autrev.2015.01.010

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  12 in total

Review 1.  Autoimmunity in 2015.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

2.  Early cerebral volume reductions and their associations with reduced lupus disease activity in patients with newly-diagnosed systemic lupus erythematosus.

Authors:  Anselm Mak; Roger Chun-Man Ho; Han-Ying Tng; Hui Li Koh; Joanna Su Xian Chong; Juan Zhou
Journal:  Sci Rep       Date:  2016-03-01       Impact factor: 4.379

3.  Cerebral Small Vessel Disease Burden Is Increased in Systemic Lupus Erythematosus.

Authors:  Stewart J Wiseman; Mark E Bastin; Charlotte L Jardine; Gayle Barclay; Iona F Hamilton; Elaine Sandeman; David Hunt; E Nicole Amft; Susan Thomson; Jill F F Belch; Stuart H Ralston; Joanna M Wardlaw
Journal:  Stroke       Date:  2016-10-04       Impact factor: 7.914

4.  Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus.

Authors:  Matteo Piga; Alberto Floris; Giulia Cappellazzo; Elisabetta Chessa; Mattia Congia; Alessandro Mathieu; Alberto Cauli
Journal:  Arthritis Res Ther       Date:  2017-11-10       Impact factor: 5.156

Review 5.  Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus.

Authors:  Alberto Floris; Matteo Piga; Arduino Aleksander Mangoni; Alessandra Bortoluzzi; Gian Luca Erre; Alberto Cauli
Journal:  Mediators Inflamm       Date:  2018-02-18       Impact factor: 4.711

Review 6.  Brain Single Photon Emission Computed Tomography Scan (SPECT) and functional MRI in Systemic Lupus Erythematosus Patients with Cognitive Dysfunction: A Systematic Review.

Authors:  Maryam Sahebari; Zahra Rezaieyazdi; Mandana Khodashahi; Bita Abbasi; Fazlollah Ayatollahi
Journal:  Asia Ocean J Nucl Med Biol       Date:  2018

7.  Are serum autoantibodies associated with brain changes in systemic lupus erythematosus? MRI data from the Leiden NP-SLE cohort.

Authors:  C Magro-Checa; S Kumar; S Ramiro; L J Beaart-van de Voorde; J Eikenboom; I Ronen; J de Bresser; M A van Buchem; T W Huizinga; G M Steup-Beekman
Journal:  Lupus       Date:  2018-12-08       Impact factor: 2.911

8.  Neuropsychiatric Lupus Erythematosus: Future Directions and Challenges; a Systematic Review and Survey.

Authors:  Yongwen Zhang; Huanhuan Han; Lanfang Chu
Journal:  Clinics (Sao Paulo)       Date:  2020-04-17       Impact factor: 2.365

9.  Severe neuropsychiatric systemic lupus erythematosus successfully treated with rituximab: an alternative to standard of care.

Authors:  Elisabetta Chessa; Matteo Piga; Alberto Floris; Alessandro Mathieu; Alberto Cauli
Journal:  Open Access Rheumatol       Date:  2017-09-11

Review 10.  Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?

Authors:  Gerwyn Morris; Eugene Athan; Ken Walder; Chiara C Bortolasci; Adrienne O'Neil; Wolf Marx; Michael Berk; André F Carvalho; Michael Maes; Basant K Puri
Journal:  Life Sci       Date:  2020-10-06       Impact factor: 6.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.